MK-7262 and Enlicitide in people with high lipoprotein(a)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 interventional study evaluates MK-7262 alone and in combination with enlicitide versus placebo for lowering lipoprotein(a) and LDL-C. Participants have elevated Lp(a) (≥150 nmol/L) and are on a stable statin regimen. The study examines safety and tolerability of the treatments, as well as potential additive effects when combining MK-7262 with enlicitide. Enrollment includes adults receiving care at select U.S. sites, with exclusions for certain cardiovascular, infectious, and liver conditions. Lead sponsor is Merck, with multiple site locations across Alabama and California.

Why it matters

Who can join: the full rules

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

* Has Lp(a) ≥ 150 nmol/L
* Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

* Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH
* Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization
* Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load)
* Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection
* Has a history of nephrotic syndrome
* Has severe renal insufficiency
* Has received certain therapies in the prohibited timeframe as specified in the protocol
* Has active or chronic hepatobiliary or hepatic disease
* Has poorly controlled Type 1 or Type 2 diabetes

Where it's running

• Advanced Cardiovascular - Alexander City ( Site 0158)
  Alexander City, Alabama, United States Recruiting
• AMR Clinical Mobile ( Site 0149)
  Mobile, Alabama, United States Recruiting
• National Heart Institute ( Site 0113)
  Beverly Hills, California, United States Recruiting
• Headlands Research CTR Lincoln ( Site 0127)
  Lincoln, California, United States Recruiting
• Chase Medical Research, LLC ( Site 0163)
  Waterbury, Connecticut, United States Recruiting
• Soffer Health Institute ( Site 0123)
  Hollywood, Florida, United States Recruiting

+26 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Toll Free Number
• Email: Trialsites@msd.com
• Phone: 1-888-577-8839

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if Lepodisiran lowers coronary plaque in people with high Lp(a) and heart disease risk

  This study tests whether lepodisiran can reduce heart-artery plaque in adults with high Lp(a) compared to placebo.

  Recruiting at 53 sites Phase 3 Eli Lilly and Company · La Jolla, California and 56 other locations · NCT07613294

• AI-assisted cardiac CT to predict coronary artery disease risk

  This project will try using AI-enhanced heart CT scans to better predict future coronary events in adults who are already getting a clinical cardiac CT.

  Recruiting University of Galway · Galway · NCT07577609

• Cardiovascular health in children and young adults with chronic conditions

  This project will see if children and young adults (ages 6-25) with chronic health conditions show early signs of aging in large and small blood vessels using noninvasive imaging and clinical tests.

  Recruiting Semmelweis University · Budapest and 2 other locations · NCT07086989

• Using heart CT imaging to find early coronary artery disease in family members with high or low lipoprotein(a)

  This study is testing if heart CT scans can help find early signs of heart disease in family members of people with high or low lipoprotein(a) levels.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT06995183

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.